EVOLVE China: A Prospective, Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)
Latest Information Update: 17 Nov 2023
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EVOLVE-China
- Sponsors Boston Scientific Corporation
- 29 Dec 2020 Status changed from active, no longer recruiting to completed.
- 20 Jul 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 02 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.